Background The COUGAR-02 trial recently showed survival and quality-of-life benefits of docetaxel and active symptom control (DXL ? ASC) over active symptom control (ASC) alone in patients with refractory oesophagogastric adenocarcinoma. Aim The aim of this study was to conduct an economic evaluation conforming to National Institute for Health and Care Excellence (NICE) technology appraisal guidance to evaluate the cost effectiveness of DXL ? ASC versus ASC from the perspective of the English National Health Service (NHS). Methods Cost-utility analyses were conducted using trial data. Utility values were captured using the EQ-5D completed by patients at 3-and 6-weekly intervals, while resource use was captured using nurse-completed report forms and patient reports. Incremental cost-effectiveness ratios (ICERs) were calculated and the main outcome was cost per incremental quality-adjusted life-year (QALY). Nonparametric bootstrapping was conducted to capture sampling uncertainty and to generate a cost-effectiveness acceptability curve (CEAC). The analysis horizon was the trial period (median follow-up 12 months) and no modelling or discounting of future costs and benefits was conducted.
Introduction
Oesophagogastric cancer is the fifth most common type of cancer in the UK and is associated with poor prognosis and survival [1] . The recent COUGAR-02 randomised, controlled, open-labelled trial (ISRCTN13366390) compared docetaxel chemotherapy plus active symptom control (DXL ? ASC) and active symptom control (ASC) only in patients in the UK with advanced adenocarcinoma of the oesophagus, oesophagogastric junction, or stomach [2] . Patients (aged 18 years and over) were included in the trial if their cancer had progressed within 6 months of treatment with a platinum-fluoropyrimidine combination. They were randomised on a 1:1 basis and those in the DXL ? ASC arm received a dose of 75 mg/m 2 of docetaxel by intravenous infusion every 3 weeks for up to six cycles. ASC included treatments for symptoms such as pain (e.g. morphone sulphate), nausea (e.g. metoclopramide) and dyspepsia (e.g. omeprazole), and included community and hospice care. The intention-to-treat analysis followed-up 168 randomised patients to a median of 12 months. Results indicated that median overall survival in the DXL ? ASC group was 5.2 months (95 % CI 4.1-5.9) versus 3.6 months (3.3-4.4) in the ASC group (hazard ratio 0.67, 95 % CI 0.49-0.92; p = 0.01). Quality-of-life and symptom reduction benefits were observed, with DXL ? ASC patients reporting less pain (p = 0.0008), less nausea and vomiting (p = 0.02), less constipation (p = 0.02), and lower dysphagia (p = 0.02) and abdominal pain (p = 0.01) than the ASC group.
The trial investigators concluded that docetaxel could be recommended as an appropriate second-line treatment for this population. The cost effectiveness of docetaxel for second-line treatments in nonsmall cell lung cancer [3] , prostate cancer [4] and breast cancer [5] has been explored with mixed results; however, few studies (e.g. Chen et al. [6] ) have evaluated the value for money of the treatment strategy in stomach or oesophageal cancers. The aim of the current analysis was to conduct a trial-based economic evaluation of DXL ? ASC versus ASC for refractory oesophagogastric adenocarcinoma from the perspective of the National Health Service (NHS) using data from the COUGAR-02 trial.
Materials and Methods
The analysis adopted National Institute for Health and Care Excellence (NICE) reference case methods [7] . As such, it employed a cost-utility approach, with costs calculated from the perspective of Health and Personal Social Services, and with the primary outcome being cost per incremental quality-adjusted life-year (QALY).
Utility Assessment
Utility was based on the EQ-5D (three-level) [8] and UK scoring tariff [9] . Patients completed the EQ-5D at baseline, during clinic visits at weeks 3, 6, 9 and 12, then every 6 weeks for up to 1 year and then every 3 months until death. QALY calculations were based on an area under the curve (AUC) approach where an average utility value was calculated between each adjacent EQ-5D completion, multiplied by the length of time between completions and divided by 365.25. Death was assumed to yield a utility value of '0'. Thus, for those who died, the last QALY contribution was taken as the average between the individual's last completed EQ-5D value and 0; this accounts for the likely deterioration in health leading up to death. As in the trial efficacy analysis, the primary economic analysis censored survival of alive patients to the date they were last known to be alive (i.e. survival was not modelled forward). An additional sensitivity analysis used Kaplan-Meierbased mean survival imputations to estimate the survival of those who were alive at study close, and calculated QALYs and costs for the additional survival period [10] .
Costs
Healthcare usage data were collected on primary care (e.g. general practitioner [GP] contacts, nurse visits), social care (e.g. social worker or home-help visits) and secondary care (e.g. hospital visits and stays). Primary and social care resource use was gathered using specially-developed questionnaires completed by patients at the same time as the EQ-5D. Two methods were used to capture secondary care resource use: (1) micro-level data using inpatient and outpatient case-report forms completed by the nurses at every contact, and costing each stay and visit based on the assessments (e.g. specialist consultant assessments and scans) received (although staff time and procedures were costed using reference costs); and (2) less granular, macrolevel costing based on bundled unit costs for stays and procedures. The base-case analysis employed costing method (1), with method (2) being used as a sensitivity analysis. Resource and equipment use were costed using unit costs from the Personal Social Services Research Unit (PSSRU) report [11] , NHS reference costs [12] , the British National Formulary [13] and the Electronic Market Information Tool (eMit) [14] . Unit costs (with the exception of medication costs) are included in electronic supplementary Tables 1-3 .
The costs for docetaxel were calculated per cycle and volume received (assuming dose = 75 mg/m 2 ) based on patients body surface area (BSA) at baseline. The net price of docetaxel infusion of 20 mg/mL: 1-mL vial was £8.47 (£7.06 ?20 % VAT) [14] and all treatments were assumed to consist of an appropriate number of these volume vials, with any mg/mL above the required level assumed to be wastage. In addition, a chemotherapy administration cost of £171 (HRG SB12Z in NHS reference costs) was included for every cycle. BSA was calculated using the DuBois method [15] and was replaced by the national average (BSA 1.79) [16] when missing. The costs for radiotherapy included £700 (NHS reference cost HRG SC46Z) for initial treatment set-up and £108 per fraction received (NHS reference cost HRG SC22Z). If the number of fractions was missing then the mean for the sample was used. All costs (with the exception of docetaxel as the list price was from June 2013) were inflated to 2014 prices using an accepted cost converter based on purchasing power parities [17] .
Analysis
If costs and effects were higher or lower for one treatment strategy over another then incremental cost-effectiveness ratios (ICERs) were calculated [18] . The ICER is calculated as (Cost DXL?ASC -Cost ASC )/(QALY DXL?ASC -QALY ASC ) and yields the cost of obtaining an additional QALY for DXL ? ASC. Interventions yielding ICERs above the NICE willingness-to-pay threshold range of £20,000-£30,000 per incremental QALY are not considered cost effective and deemed an inefficient use of scarce resources; however, exceptions to the case may be made if a treatment extends life and meets the NICE 'end-of-life' criteria [7] . Analyses explored the scenario where the endof-life weighting is applied and the QALY gain (or threshold) is multiplied by 2.5.
Nonparametric bootstrapping (n = 10,000 simulations with replacement) was employed to determine the level of sampling uncertainty around the estimates of cost effectiveness. The resulting 10,000 incremental costs and effects are plotted on a cost-effectiveness plane. The ICER decision rule can be reformulated to generate incremental net monetary benefit (INMB) in the following manner: INMB = k 9 (QALY DXL?ASC -QALY ASC ) -(Cost DXL?ASCCost ASC ), where k is the NICE threshold value. If INMB is positive given a particular k, then DXL ? ASC is considered cost effective. The bootstrapped NMB values were used to identify the probability that DXL ? ASC was cost effective given a range of k, presented on a cost-effectiveness acceptability curve (CEAC) [19] , and to determine nonparametric confidence intervals [20] . The net benefit regression framework was applied to permit parametric analysis of cost-effectiveness controlling for heterogeneity [21] .
Multiple imputation (m = 20) based on a combination of predictive mean matching (pmm), logit and Poisson models, depending on the variable type, was used to handle missing data [22] . Hospital visits, medication, radiotherapy and docetaxel costs were not imputed. Ambulance use, assessments and length of stay for hospital visits were imputed using treatment, demographic and clinical variables (e.g. cancer site, tumour type, previous surgery). EQ-5D utilities were imputed using the same variables when all items were missing, and using additional information from completed items when only some were missing. Community care total costs were imputed using the same variables and average community care costs from completed patient forms and patient secondary care costs. The means of the imputed values were used in the final analyses.
A number of sensitivity analyses were conducted to test the sensitivity of the cost-effectiveness estimates to the methods adopted. Specifically, we tested the impact of adopting different secondary care costing approaches (micro vs. macro); assuming fewer outpatient visits for chemotherapy; extrapolating QALYs forward for survivors; 10-20 % changes in costs and QALYs to account for errors in cost and benefit calculation; and adjusting for baseline EQ-5D. Discounting was not considered necessary as, with the exception of a few instances, all costs and effects were observed within 12 months. All analyses were conducted using STATA 13Ó (StataCorp LP, College Station, TX, USA) and ExcelÓ (Microsoft Corporation, TX, USA).
Results
Data were available from all 168 patients (84 patients in each arm). At the time of the analysis, 161 of the 168 (96 %) patients had died, leaving only 7 patients alive and therefore with censored data. Of the 1171 expected patient resource use forms, after accounting for survival, 527 (45 %) were completed. Multiple imputation was used to estimate the costs from the missing forms; however, the primary care use reported therein represented a small proportion of overall costs and therefore imputation made little impact on the results. For example, community care mean (standard deviation [SD]) costs per timepoint for observed and imputed cases for the combined sample were £127.95 (£360.42) and £119.60 (£147.71), respectively. Information on medication use and number of inpatient and outpatient stays was assumed complete as these were based on case-report forms completed by nurses; however, some data were missing within these forms (for example, for 117 [50 %] of 233 inpatient stays, details regarding ambulance use was missing) and this was also imputed. In general, missing data were minimal, with less than 4 % of stay length, ward type and EQ-5D scores missing.
DXL ? ASC patients received a median of three chemotherapy cycles (interquartile range [1] [2] [3] [4] [5] Table 4 ); visited A&E on 0.13 occasions (SD 0.43; range 0-3) compared with 0.01 (SD 0.11; range 0-1) in the ASC arm; and visited the GP on 1.12 occasions (SD 2.14; range 0-9) compared with 0.87 occasions (SD 1.17; range 0-5) in the ASC arm (electronic supplementary Table 5 ). Thus, resource use was higher in the DXL ? ASC arm than the ASC arm in most areas. There were over 2300 prescriptions of medication during the study, of which the most common were for relief of pain (23 %), nausea (12 %), constipation (7 %) and gastric symptoms such as dyspepsia (6 %).
Resource use costs (after imputation) are included in Table 1 . Patients incurred both higher primary and secondary care costs in the DXL ? ASC group. Medication costs (excluding docetaxel itself) were higher in the DXL ? ASC group than the ASC group (£192 vs. £96). Of the prescription costs, 23 % were less than £1, 75 % were less than £5, and 99 % were less than £100. Mean medication costs of preventing and treating neutropenia and related sepsis were £8.89 (SD £25.01) and £0.00 for the DXL ? ASC and ASC arms, respectively. The costs of medication for preventing and treating nausea and vomiting were £31.95 (SD £53.28) and £14.58 (SD £37.17) for the DXL ? ASC and ASC arms, respectively. On average, Table 1 Costs docetaxel chemotherapy costs were £798 and ranged from £236 to £1770, while radiotherapy costs were substantively higher in the ASC group (£275 vs. £15 for the DXL ? ASC group). Inpatient costs were £1632 higher in the DXL ? ASC group than the ASC group, and this appeared to be driven by bed day costs. On average, outpatient costs were £674 greater in the DXL ? ASC group, which was driven by the higher number of visits and investigation costs. In total, DXL ? ASC was found to be £3134 (£9352 vs. £6218) more expensive than ASC alone.
Baseline utility values were similar across arms (DXL ? ASC 0.69; ASC 0.70); however, an analysis adjusting for this difference was conducted as a sensitivity analysis [23] . Figure 1 shows the quality-adjusted survival based on EQ-5D scores up to week 60, and shows a greater AUC for DXL ? ASC compared with ASC, with the former group experiencing average QALYs of 0.302 compared with 0.186 in the ASC group, an incremental QALY gain of 0.116 (see electronic supplementary Table 6 for utility values). Table 2 includes average patient costs and QALYs per trial arm as well as ICERs for the base-case and sensitivity analyses. The results for the base-case analysis indicate that DXL ? ASC confers higher QALYs than ASC, and is more costly. The mean bootstrapped ICER of £27,123 is above what is usually considered cost effective, although well below a threshold of £50,000 following the application of the NICE end-of-life criteria. The results are robust to a number of sensitivity analyses where alternative costing and QALY calculation methods are employed and when cost and QALY estimates are varied by 20 % (Table 2) . Reductions in costs and increases in QALYs (in both arms) by 20 % leads to ICERs approaching £20,000.
It is worth noting that the macro-costing approach has the effect of reducing estimated costs in both arms but the overall effect on the ICER is minimal. Extrapolating the survival forward for individuals alive at trial end has minimal impact on QALYs gained and the ICER, partly due to the small number surviving the trial and because some of those are in health states worse than dead (i.e. their EQ-5D value is negative). Adjusting for baseline EQ-5D also had minimal impact on the ICER. Figure 2 illustrates that most of the simulated ICERs are in the north-east quadrant of the cost-effectiveness plane, with approximately one-third falling below the (£20,000) cost-effectiveness threshold. The CEAC is presented in Fig. 3 and shows that, where k = £20,000 and k = £30,000, DXL ? ASC has a 24 and 59 % chance, respectively, of being cost effective. Ceteris paribus, the cost differential would have to be £2306 or less, or the QALY differential 0.16 or more, for the ICER to fall under £20,000.
The INMB means at thresholds of £20,000, £30,000 and £50,000 were -£821, £332 and £2638, respectively ( Table 2 ). For the same thresholds, net benefit regression indicated that, both with and without demographic and clinical covariates, the treatment arm was not a significant predictor of net benefit (see electronic supplementary Table 7 ). There was a trend (at k = £30,000) for those who had received previous surgery to derive greater net benefit (incremental £3664; 95 % CIs -£277 to £7607; p = 0.068) than those who had not. Interactions with the treatment variable also indicated there may be a differential treatment effect according to gender and tumour type (metastatic vs. locally advanced). Eastern Cooperative Oncology Group (ECOG) performance status was an important predictor of NMB, with those in better health accruing greater benefit. The ECOG 9 treatment interaction was not significant but suggested that chemotherapy was of greatest benefit over ASC in those with better performance status at trial outset.
Discussion
This economic evaluation conducted alongside the COU-GAR-02 randomised clinical trial found that a strategy of DXL ? ASC versus ASC alone was more costly but was associated with greater benefits for refractory oesophagogastric adenocarcinoma. The cost per incremental QALY was, at approximately £27,000, above that normally considered cost effective. Exploring the sampling uncertainty around the estimate revealed that chemotherapy had a 24 % chance of being cost effective; however, at a willingness-to-pay threshold of £30,000, there was a 59 % chance of chemotherapy being cost effective and a mean INMB of £332. The ICERs remained in the range of £20,000-£30,000 after a series of deterministic sensitivity analyses, providing some confidence in the robustness of the results. The cost differential was £3134, and would need to fall by £828 for the ICER to drop below £20,000; this is approximately equivalent to two nights in hospital plus two outpatient visits. The incremental benefit of 0.116 Bootstrap simulated net monetary benefit c (unadjusted) Willingness-to-pay threshold (k) k = £20,000 k = £30,000 k = £50,000
DXL ? ASC docetaxel and active symptom control, ASC active symptom control, ICER incremental cost-effectiveness ratio, QALY qualityadjusted life-year, CI confidence interval, k lambda/willingness-to-pay threshold a Assumes one (higher) cost per (inpatient and outpatient) visit and excludes diagnostics, tests, assessments and other surgery; for DXL, assumes outpatient cost includes chemotherapy administration b Removes outpatient visits at 3, 9 and 15 weeks c Confidence intervals based on 2.5th and 97.5th percentiles or present non-UK data only [6] . Within these studies, findings were mixed as to whether docetaxel was cost effective [3] or not [5, 6] , with ICERs ranging between £23,000 and £33,000; however, the ICERs are clearly context-dependent and determined by the definition of standard care and comparators. It is possible that the treatment strategy would be eligible for the end-of-life criteria set out by NICE [7] . These criteria have been challenged on ethical [24] and efficiency grounds [25] , and although they may not reflect the preferences of society [26] , they are still worthy of consideration. The NICE Appraisal Committee may accept analyses with additional QALY weightings where (1) the life expectancy of the group is less than 24 months; (2) there is evidence that life is extended by a minimum of 3 months; and (3) the population in England eligible for treatment is less than 7000. Patients in this group would certainly meet the criteria of life expectancy of less than 24 months. A recent audit revealed that 9768 patients with oesophagogastric cancer were treated with palliative treatment intent in England in 2011-2012 [1] ; as only a proportion would be receiving second-line chemotherapy, the annual eligible population would be less than 7000. While the NICE end-of-life criteria (1) and (3) are met, satisfaction of (2) is less clear as additional median life extension was 1.6 months (5.2 vs. 3.6 months) [mean 1.8 months (6.6 vs. 4.8)] in the statistical evaluation; however it is likely that appraisal committees may have some flexibility in this regard. Should the criteria apply here, and the willingnessto-pay threshold be increased to £40,000 or £50,000 per QALY (effectively a QALY weighting of 2 and 2.5, respectively), then the probability that the DXL ? ASC strategy would be cost effective is 81 % (mean INMB £1485) or 90 % (mean INMB £2638).
The data presented here are arguably more complete than that normally available to NICE Evidence Review Groups, and demonstrate that, even for an inexpensive treatment, it may be difficult to achieve cost effectiveness. A possible conclusion is that, in order to achieve an ICER less than £20,000, new treatments (which are generally more expensive) would need to show very much higher levels of effectiveness or lower resource use. The cost used here for docetaxel is the genericized price and is unlikely to decrease significantly in the future. Ramucirumab provides similar survival gains but costs more than £7000 per cycle (total more than £28,000) compared with approximately £50 per cycle for docetaxel (total approximately £150). Consequently, ramucirumab would need to provide ceteris paribus more than an additional year of life (at full health) to achieve cost effectiveness. This is almost certainly not achievable in a disease with a current median survival of \6 months, and hence novel treatments are unlikely to become available to UK patients at this price level. The NHS, industry and society need to consider the implications of this and agree a way forward that will provide affordable access to innovative medicines. 
Limitations
The analyses were somewhat reliant (for the costs, at least) on multiple imputation, which may have introduced additional uncertainty that was not fully captured or was underestimated in the analysis; however, data on survival, utility and secondary care costs were relatively complete. Furthermore, since imputation had the largest role in dealing with missing community care costs, which were a small proportion of overall costs, it is unlikely that it would have influenced results substantively. We assumed that nurse-completed case reports were accurate in that inpatient and outpatient visits were captured fully, but this may not have been the case and resource use may consequently have been underestimated. While the exploration of ±20 % costs in both arms allows confidence that the decision would not change, this assumes that missing data and recording errors were equalised across arms. Any errors in accounting, such as double counting, may be greater for the DXL ? ASC arm as there was more resource use therein. This evaluation used data from a single trial only. If there is sufficient decision uncertainty remaining in this clinical area, a model-based evaluation may be worthwhile as this would allow synthesis of effectiveness data from COU-GAR-II and other docetaxel trials (e.g. Kang et al. [27] ), and permit comparisons with alternative therapies such as ramucirumab (e.g. Fuchs et al. [28] ).
Finally, the analysis took the perspective of the NHS and omitted costs to the patient and their carers. If a wider perspective had been adopted it is likely that the results would have been less favourable for DXL ? ASC since the private costs of travelling to hospital would have been higher in the DXL ? ASC arm.
Future Research
As in the trial effectiveness analysis, there was a suggestion from the net benefit analysis conducted here that the benefits of chemotherapy might be greater in those who are in better health initially (according to ECOG performance status). Future studies of chemotherapy in advanced disease should be powered to enable subgroup analyses to explore this trend more thoroughly.
Although the EQ-5D has been validated in cancer patients [29] , there is evidence that it lacks sensitivity in this group [30] , omits key constructs of importance and overstates the benefits of chemotherapy [31] . Recent efforts have sought to develop preference-based measures that capture issues such as nausea, constipation and other cancer-related issues [32] . Future analyses should explore the impact of (disease-specific) measure choice on estimates of cost effectiveness. We found that there were nontrivial differences (£1204) in costs according to the methods used, with macro-costing yielding a figure 13 % lower than micro-costing. This difference did not change the decision here, but macro-level costing is common in economic studies and this approach may underestimate healthcare costs. Future analyses should be mindful of the impact of costing methods and, where possible, consider collecting micro-level data.
Assuming the QALY benefits observed in this study (after accounting for side effects) are accurate and reflect true additional patient benefit, an obvious approach to enhancing the value of the chemotherapy strategy examined here would be to reduce delivery costs. The study protocol included visits every 3 weeks until week 18, which may be above that which would be expected in routine practice. Removing these and assuming visits every 6 weeks reduced the ICER to £25,986. Alternative approaches such as home delivery of intravenous chemotherapy may be a fruitful avenue for research. Such an intervention may bring additional quality-of-life benefits as it is known that those who are treated at the end of life would prefer to receive treatment at home [33] , and it would also reduce resource costs [34] .
Conclusions
The docetaxel strategy had survival and quality-of-life benefits over ASC alone but was more costly. It was not deemed to be cost effective unless additional 'end-of-life' QALY premiums were applied. The additional costs of chemotherapy delivery and patient resource use were important drivers of cost effectiveness, and future research should explore ways in which to reduce these. The analyses highlight important, more general issues, i.e. that novel treatments may continue to struggle to overcome the valuefor-money hurdle when providing only modest benefits in patients with poor prognosis; that reliance on patient reports for resource use in populations with severe disease may result in high levels of missing data; and that the methods of costing (micro vs. macro) may impact results.
